Optipharm Acquires Two Patents Related to Antibacterial Compositions
[Asia Economy Reporter Oh Ju-yeon] Optipharm announced on the 13th that it has acquired patents for a novel Bacteriophage EF5 specific to Clostridium perfringens and an antimicrobial composition containing it, as well as a novel Bacteriophage CS3 specific to Cronobacter sakazakii and an antimicrobial composition containing it.
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- Laundering 117 Billion Won with Chinese Syndicate: Illegal Bank Account Ring Referred to Prosecutors
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "These are antibiotic alternative substances that can effectively eliminate pathogenic bacteria causing diseases," adding, "We plan to utilize these bacteriophage resources, which can control major antibiotic-resistant bacteria and foodborne pathogenic bacteria, in various fields to develop preventive and therapeutic agents that can remove causative bacteria. We also intend to actively use them to establish a bacteriophage-based drug platform."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
